Amyris (AMRSQ) Form 3 AMYRIS / DSM N.V. Koninklijke ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

DSM International B.V.

(Last) (First) (Middle)

HET OVERLOON 1

(Street)

HEERLEN P7 6411 TE

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/07/2017

3. Issuer Name and Ticker or Trading Symbol
AMYRIS, INC. [ AMRS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	(1)	(1)	Common Stock	3,968,116	(1)	I	See footnote(2)
Warrants (right to buy)	07/07/2017	07/07/2022	Common Stock	1,984,058	0.52	I	See footnote(2)
Warrants (right to buy)	07/07/2017	07/07/2022	Common Stock	1,984,058	0.62	I	See footnote(2)

1. Name and Address of Reporting Person^*

DSM International B.V.

(Last) (First) (Middle)

HET OVERLOON 1

(Street)

HEERLEN P7 6411 TE

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Koninklijke DSM N.V.

(Last) (First) (Middle)

HET OVERLOON 1

(Street)

HEERLEN P7 6411 TE

(City) (State) (Zip)

Explanation of Responses:

1. Each share of Series B preferred stock is convertible at any time at the option of the holder into Common Stock of the Issuer on an approximately 1-to-158.7 basis. The Series B preferred stock has no expiration date.

2. The securities reported herein are held of record by DSM International B.V., which is a wholly owned subsidiary of Koninklijke DSM N.V. Accordingly, Koninklijke DSM N.V. may be deemed to share beneficial ownership of the securities held of record by DSM International. Koninklijke DSM N.V. is a publicly traded company with securities listed on the Amsterdam Stock Exchange.

	DSM International B.V. By: /s/ Hugh Welsh, President, DSM North America	07/17/2017
	Koninklijke DSM N.V. By: /s/ Hugh Welsh, President, DSM North America	07/17/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.